If cost is a barrier prompting consideration of less frequent dosing, discuss this openlypatient assistance programs, alternative GLP-1 receptor agonists, or other therapeutic options may be available
FDAs approval of Wegovy (a higher-dose version of semaglutide), clinical trials showed that patients lost an average of 15% of their body weight over time
"Half a plate at dinner and I'm done
They are specifically designed to reduce the incidence and severity of nausea, vomiting, and diarrhea during the early weeks of treatment
Disclosure of interest: Diego Torres Nuez: nothing to disclose, Maria Esther Llorente Iniesta: nothing to disclose, Ramon Miano Monedero: nothing to disclose, Francisco Martinez Garcia: nothing to disclose, Angel Valero Lopez: nothing to disclose, Carmen Maria Sanchez Garcia: nothing to disclose, Pedro Lucas Arnaldos Illan: nothing to disclose, Maria Obdulia Lozano Caballero: nothing to disclose, Laura Albert Lacal: nothing to disclose, Ainara Sanz Monllor: nothing to disclose, Estefania Garcia Molina: nothing to disclose, Cesar Lucas Rodenas: nothing to disclose, Maria Dolores Espinosa Garcia: nothing to disclose, Eduardo Pinar Bermudez: nothing to disclose, Ana Morales: nothing to disclose E-Posters - DIAGNOSIS / ETIOLOGY 04.00 - DIAGNOSIS / ETIOLOGY - 04.04 - RARE CAUSES INCL
We also offer nutritional counseling, fitness guidance, and ongoing support to ensure your success